Study participants were asked about their interest in switching to novel drug delivery
systems that reduce the dosing frequency of antiretroviral regimens. Across a diverse …

Background Antiretroviral treatment (ART) for patients living with HIV (PLHIV) has improved
greatly, however, challenges with daily oral dosing remain. New ART options with reduced …

Managing antiretroviral therapy (ART)–experienced individuals requires a systematic
approach in order to optimize outcomes. Consideration must be given to the different …

Use of long-acting injectable antiretroviral therapy depends on patient awareness, provider
discussion, and patient willingness to use. We conducted a postvisit survey with patients at 3 …

Objective The objective of this study was to understand patient preferences for contemporary
antiretroviral therapy (ART) by focusing on three areas that have been understudied …

The objective of the study was to describe the potential expectation and acceptability of
injectable ARTs by PLHIV followed in our infectious diseases department. The survey was …

Abstract In January 2021, cabotegravir/rilpivirine, the first extended-release injectable
regimen for the treatment of Human Immunodeficiency Virus (HIV) was approved. Long …

The study evaluates the acceptability and preferences for long-acting antiretroviral therapy
(LA-ART) among a diverse cohort of people with HIV infection (PWH). It consists of a self …

Introduction Recent advances in long‐acting antiretroviral therapy (LA‐ART) could provide
new options for HIV treatment and reduce adherence barriers, if regimens are acceptable to …

Introduction: The use of lifelong antiretroviral therapy (ART) results in increased costs of
care; the ability to finance and control sustained costs of ART needs to be discussed …